In the DoRIS trial in Mwanza, antibody levels two years after a single dose of HPV vaccine in girls aged 9 to 14 were not inferior to those in cohorts where one dose had protected for up to 11 years, supporting a one-dose schedule.
Published as "Comparing one dose of HPV vaccine in girls aged 9-14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial". DoRIS (NCT02834637) enrolled 930 girls from 54 government schools in Mwanza in 2017 and 2018 and randomised them to one, two or three doses of the 2-valent or 9-valent vaccine.
Tanzanian girls in this trial gave part of the evidence that one dose of HPV vaccine may be enough, the schedule Tanzania itself adopted in 2024.
Shares Ministry of Health, Tanzania, HPV & HBV vaccination, Cervical cancer.
Shares HPV & HBV vaccination, Cervical cancer.
Shares HPV & HBV vaccination, Cervical cancer.
Shares HPV & HBV vaccination, Cervical cancer.
Shares HPV & HBV vaccination, Cervical cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/